Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

in an open-label fashion for another 12 to 24 weeks. Forty-seven percent (47%) achieved a response as defined by clear or almost clear hands. These results further confirm the efficacy of alitretinoin in patients with CHE refractory to topical therapy.

Alitretinoin was generally well tolerated with a safety profile similar to that reported in previous phase II and phase III clinical studies. The most frequent adverse events were headache and blood lipid elevations.

Dr. Anthony Man, CEO of Basilea said, "Because of the relapsing nature of Chronic Hand Eczema it was important for patients and treating physicians that we further characterize the safety and efficacy of more than one treatment course of alitretinoin. These trial results confirm that alitretinoin is an effective treatment for severe refractory Chronic Hand Eczema. Alitretinoin has the potential to be integrated into pragmatic re-treatment algorithms for these chronically affected patients who have limited treatment options."

About Chronic Hand Eczema (CHE) Hand eczema is a common skin disease and is often chronic and relapsing. It is estimated to affect up to 10% of the general population. The more severe, chronic form of the condition is thought to affect up to 7% of these patients, many of whom do not respond, or no longer respond to topical corticosteroids. Basilea estimates there are at least one million patients in Europe and North America with refractory severe CHE for which currently no approved, effective pharmaceutical treatment is available.

For the patient, severe CHE can be a frustrating and debilitating disease. Patients often suffer for years from erythema, blisters, vesicles, scaling and fissures which can cause chronic pain and functional impairment of the hands. Studies suggest these patients have a significantly reduced quality of life and the majority experience social or emotional distress and sleep disorders. It is reported that up to 20% of sufferers have
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:12/16/2009)... -- Siemens Healthcare today announced a ... to help healthcare providers pursue ... within the HITECH provision of the American ... Featuring zero-percent interest terms for qualified customers, ... payments associated with their technology investment while ...
(Date:12/16/2009)... -- Biovista Inc.,today announced that it was awarded ... the 2009 New England Venture Summit, held on ... cutting edge private companies,driving the future of innovation, ... other privately held companies that play a leading ... Clean-tech sectors. , "We ...
(Date:12/16/2009)... Avantium announced the,appointment of Gunnar Staaf as ... Staaf previously worked at Serentis Ltd, Astellas ... a range of commercial and executive,positions. The ... plan to,spin-out its pharmaceutical business. The company ... on its offering of proprietary,crystallization services and ...
Breaking Medicine Technology:Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4Biovista Inc. Named Top Innovator in Life Sciences 2Avantium Appoints Gunnar Staaf as CEO Pharma 2Marteks lifesDHA 28TM 29 Featured in New Nutrioli DHA Cooking Oil from Ragasa 57854 1Marteks lifesDHA 28TM 29 Featured in New Nutrioli DHA Cooking Oil from Ragasa 57854 2Marteks lifesDHA 28TM 29 Featured in New Nutrioli DHA Cooking Oil from Ragasa 57854 3Many Teens Circumvent Tanning Bed Laws 57851 1Many Teens Circumvent Tanning Bed Laws 57851 2Many Teens Circumvent Tanning Bed Laws 57851 3The doctor can understand you now 57848 1The doctor can understand you now 57848 2The doctor can understand you now 57848 3
... Infectious Disease Specialist, also available as,Expert Resource, FLUSHING, N.Y., Oct. 30 The following ... A special briefing on methicillin-resistant Staphylococcus ... James Rahal, M.D., and a ... specialists from New York Hospital Queens will address the ...
... Oct. 30 Leading researchers,will present 68 ... (peginterferon alfa-2b) and REBETOL(R),(ribavirin, USP) combination therapy, ... of chronic hepatitis C, at the 58th ... (AASLD) Annual Meeting in Boston, Nov. 2-6. ...
Other Medicine Technology:Hospital to Hold MRSA Briefing for Media and Community Leaders 2Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 7
(Date:12/16/2009)... Cost-Effective Care , ... Washington, D.C. (Vocus) December 16, ... ways to rein in runaway costs while providing care to all ... the ongoing discussion includes how to ensure patients equal access to ... (MDs) or osteopathy (DOs). In both the House and Senate ...
(Date:12/16/2009)... been found, , , WEDNESDAY, Dec. 16 (HealthDay News) -- ... food poisoning and the stomach pain and diarrhea that ... urinary tract infections. , Researchers have found the same ... restaurants and in women with the infections. , ... to the women through the food they ate, although ...
(Date:12/16/2009)... NSRTSM is found very effective in the alleviation of symptoms ... chronic fatigue and a wide array of skin conditions. ... holistic therapy including over 50 branded BioVeda Health and Wellness ... ... December 14, 2009 -- BioVeda Health and Wellness Centers, LLC. ...
(Date:12/16/2009)... not be determining factor for use, expert says, , , ... heart failure are much less likely to die when ... study. , The study included 4,685 people, ages 65 ... had a left ventricular fraction (a measure of the ... During a three-year period, those who were treated with ...
(Date:12/16/2009)... also at all-time low, government report shows, , , WEDNESDAY, ... the United States has reached almost 78 years, a ... birth in 2007, women can expect to live to ... according to the report from the U.S. Centers for ... Americans can expect to live longer than their parents, ...
Breaking Medicine News(10 mins):Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5Health News:Implanted Defibrillator Might Extend Life 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3
... Physical Therapy, one of,Los Angeles, most innovative, ... services, is the first and,only physical therapy ... G-Trainer anti-gravity treadmill for athletic training and ... facilities using the G-Trainer have,noted faster recovery ...
... 2008 --- A study conducted by a team of ... demonstrates that CT (computed tomography) perfusion imaging - a ... most hospitals - may dramatically improve fast and accurate ... and helping avoid potentially life-threatening complications of "clot buster" ...
... YORK, Oct. 29 A new report released,today by ... Democracy,finds that many of this country,s dangerous government-approved drugs ... these products,were removed or made safer only after women ... BITTEREST PILL -- How Drug Companies,Fail To Protect Women ...
... 29 Morria Biopharmaceuticals Plc, a,biopharmaceutical company ... announced today the preliminary results from its,recently ... in a nasal aerosol,formulation, in 105 patients ... multi-dose, double-blind, placebo-controlled study,included Rhinocort(R) as the ...
... in the digestive tract make occasional digestive issues more likely. In ... every year, and as many as 40% of older, boomer-aged adults ... has launched the answer for baby boomers wondering what happened to ... ...
... cancer tissues was detected by immunohistochemistry (IHC), Western ... by Its correlation Western blotting and RT-PCR. Livin ... increasing with tumor progression. Expression of Livin and ... In the fourth clinical stage, expression of Livin ...
Other Medicine News:Health News:Evolution Physical Therapy First Clinic in Southern California to Introduce NASA-Designed Anti-Gravity Treadmill for Public Use 2Health News:Evolution Physical Therapy First Clinic in Southern California to Introduce NASA-Designed Anti-Gravity Treadmill for Public Use 3Health News:WVU study demonstrates efficacy of CT perfusion in diagnosis of acute ischemic stroke 2Health News:WVU study demonstrates efficacy of CT perfusion in diagnosis of acute ischemic stroke 3Health News:New Report Shows How Drug Industry Immunity Would Endanger Women 2Health News:Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis 2Health News: What Boomers Need to Know About Digestion; Enzymatic Therapy's CompleteGest1 Renew targets special digestive issues 2Health News:A potential targets for the prevention or treatment of esophageal carcinoma 2
... whisper quiet, compact system is perfect for ... accurate and cost effective microhematocrits are required. ... CritSpin System offers a range of important ... packing - Meets NCCLS standards - Read ...
... personal Microcentrifuge with swinging bucket rotor. ,The ... centrifuge with a swinging bucket rotor and ... ideal for a variety of clinical, biomedical, ... pellet formation of a "swinging bucket centrifuge ...
... a unique closed system for performing fast, ... CenSlide 2000 system is microprocessor controlled to ... speed for one minute. At the end ... distributed evenly across the viewing area for ...
... internal drainage from the ureteropelvic ... sterile in peel-open packages. Intended ... evaluation is advised; polyurethane, C-Flex, ... remain indwelling more than six ...
Medicine Products: